ST. HELIER, Jersey--( BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today positive top-line results from its STELLAR phase 2 pilot trial in mesothelioma demonstrating clinically meaningful improvements in overall survival and progression free survival among patients who received Tumor Treating Fields plus standard of care chemotherapy, pemetrexed and cisplatin or carboplatin, compared to historical control data of patients who received standard of care chemotherapy alone.
Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться